Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
The treatment of cancer, especially of various types of solid tumors, has been revolutionized by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success amongst hematologic malignancies, however, has been limited so far to the treatment of classic Hodgkin's lymphoma, wh...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2018-11-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02431/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|